Domenico Bellomo
Research Subjects
Domenico Bellomo has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Rentroia-Pacheco
Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands
2 shared publications - Harmen J. G. van de Werken
Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Immunology, Rotterdam, The Netherlands
2 shared publications - Marlies Wakkee
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center , Rotterdam
2 shared publications - Alan Hunter Shain
Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA
1 shared publication Alexander M.M. Eggermont
Princess Máxima Center, Utrecht, the Netherlands
1 shared publication- Alexander Meves
Department of Dermatology Mayo Clinic Rochester Minnesota USA
1 shared publication
Latest Publications
- Open Access
Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of cancer worldwide. While most cSCCs are not life-threatening, 2-5% of patients develop metastases. To better understand what causes some cSCCs to progress to metastatic disease, we assembled a nationwide cohort of 19,120 patients with clinico-pathologically annotated tumors linked to metastatic outcome. RNA-sequencing was performed on 378 tumors, and whole-exome sequencing on 147, with balanced numbers of tumors that progressed to metastatic disease (cases) and did not (controls). UV radiation was the dominant mutational signature with additional contributions from aging, APOBEC activity, and, in immunosuppressed patients, azathioprine exposure. We identified 38 genes under selection across a core set of signaling pathways. Gene expression clusters were primarily associated with the differentiation state of tumor cells and secondarily with the composition of the tumor microenvironment. Several mutational and transcriptional programs were associated with metastasis, including a dedifferentiated gene expression signature, activating mutations in the RAS signaling pathway, loss-of-function alterations in the SWI/SNF chromatin remodeling complex, and specific arm-level copy number alterations. A 23-gene expression signature was built to predict metastasis from primary cSCC tissue. The signature was validated in two independent cohorts (N=102 and 52), where it predicted metastasis independently of staging systems. Together, these findings provide the most detailed molecular portrait of cSCC to date and establish an assay for risk stratification suitable for clinical implementation.
Open AccessComprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of cancer worldwide. While most cSCCs are not life-threatening, 2-5% of patients develop metastases. To better understand what causes some cSCCs to progress to metastatic disease, we assembled a nationwide cohort of 19,120 patients with clinico-pathologically annotated tumors linked to metastatic outcome. RNA-sequencing was performed on 378 tumors, and whole-exome sequencing on 147, with balanced numbers of tumors that progressed to metastatic disease (cases) and did not (controls). UV radiation was the dominant mutational signature with additional contributions from aging, APOBEC activity, and, in immunosuppressed patients, azathioprine exposure. We identified 38 genes under selection across a core set of signaling pathways. Gene expression clusters were primarily associated with the differentiation state of tumor cells and secondarily with the composition of the tumor microenvironment. Several mutational and transcriptional programs were associated with metastasis, including a dedifferentiated gene expression signature, activating mutations in the RAS signaling pathway, loss-of-function alterations in the SWI/SNF chromatin remodeling complex, and specific arm-level copy number alterations. A 23-gene expression signature was built to predict metastasis from primary cSCC tissue. The signature was validated in two independent cohorts (N=102 and 52), where it predicted metastasis independently of staging systems. Together, these findings provide the most detailed molecular portrait of cSCC to date and establish an assay for risk stratification suitable for clinical implementation.
- Open Access
- 19 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102150
Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model
- 19 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102150
Open AccessPersonalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model
- 1 November 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 140, 11-18
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
- 1 November 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 140, 11-18
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model